- CNBC - Sep 9, 2020 -
“I know there are a lot of public voices talking about when vaccines will be ready, but the fact of the matter is you can’t rush science,” Merck CEO Kenneth Frazier told CNBC on Wednesday.
Frazier’s Merck was among the nine companies that signed a pledge to prioritize safety as the drugmakers seek regulatory approval.
“When you’re putting these vaccines into healthy people, you have to do everything possible to ensure that these vaccines are both safe and effective,” Frazier said on “Fast Money: Halftime Report.”
Merck CEO Kenneth Frazier on Wednesday emphasized the need for patience and strict adherence to scientific principles in the global push to develop a vaccine to prevent the coronavirus.
“I know there are a lot of public voices talking about when vaccines will be ready, but the fact of the matter is you can’t rush science,” Frazier said on CNBC’s “Fast Money: Halftime Report.”
Frazier’s comments come one day after Merck and other leading vaccine developers, from both the U.S. and the U.K., issued a pledge to make safety the top priority as they seek regulatory approval. And later Tuesday, AstraZeneca, another signatory of the letter, said it was putting its late-stage vaccine trial on hold due to safety concerns, with one participant in the U.K. having a possible serious adverse reaction. The company called it a “routine action” that “has to happen whenever there is a potentially unexplained illness in one of the trials.”